Evidence map›Paper›PMID 40630596›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Dynamic frame-by-frame motion correction for

Meghana Urs, Aditya Killekar, Valerie Builoff, Mark Lemley, Chih-Chun Wei, Giselle Ramirez, Paul Kavanagh, Christopher Buckley, Piotr J Slomka

Registry-linked trialAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01347710 (A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01347710 phase3completednot on this map

A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)

TypeinterventionalSponsorLantheus Medical ImagingRan2011 to 2013Enrolled795ConditionsCoronary Artery DiseaseArmsFlurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Meghana UrsDepartment of Medicine (Division of Artificial Intelligence in Medicine), Cedars-Sinai Medical Center, Los Angeles, CA.
Aditya KillekarDepartment of Medicine (Division of Artificial Intelligence in Medicine), Cedars-Sinai Medical Center, Los Angeles, CA.
Valerie BuiloffDepartment of Medicine (Division of Artificial Intelligence in Medicine), Cedars-Sinai Medical Center, Los Angeles, CA.
Mark LemleyDepartment of Medicine (Division of Artificial Intelligence in Medicine), Cedars-Sinai Medical Center, Los Angeles, CA.
Chih-Chun WeiDepartment of Medicine (Division of Artificial Intelligence in Medicine), Cedars-Sinai Medical Center, Los Angeles, CA.
Giselle RamirezDepartment of Medicine (Division of Artificial Intelligence in Medicine), Cedars-Sinai Medical Center, Los Angeles, CA.
Paul KavanaghDepartment of Medicine (Division of Artificial Intelligence in Medicine), Cedars-Sinai Medical Center, Los Angeles, CA.
Christopher BuckleyGE Healthcare, Pharmaceutical Diagnostics, Buckinghamshire, UK.
Piotr J SlomkaDepartment of Medicine (Division of Artificial Intelligence in Medicine), Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-6110-938X

Funding

Patient-specific Outcome Prediction from Cardiovascular Multimodality Imaging by Artificial IntelligenceR35HL161195 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI Piotr J Slomka · 2022 to 2026
$5.0M
Integrating Artificial Intelligence for Optimal Analysis of CardiacPET/CTR01EB034586 · NIBIB · CEDARS-SINAI MEDICAL CENTER · PI DI CARLI, MARCELO F, SLOMKA, PIOTR J · 2022 to 2025
$2.9M
NHLBI NIH HHS R35 HL161195NIBIB NIH HHS R01 EB034586
6 · The paper itself

Abstract

Purpose: Precise quantification of myocardial blood flow (MBF) and flow reserve (MFR) in Methods: The method employs a 3D ResNet based architecture that takes 3D PET volumes and outputs motion vectors. It was validated using 5-fold cross-validation on data from 32 sites of a Phase III clinical trial (NCT01347710). Manual corrections from two experienced operators served as ground truth, and data augmentation using simulated vectors enhanced training robustness. The study compared the DL approach to both manual and standard non-AI automatic MC methods, assessing agreement and diagnostic accuracy using minimal segmental MBF and MFR. Results: The area under the receiver operating characteristic curves (AUC) for significant CAD were comparable between DL-MC MBF, manual-MC MBF from Operators (AUC=0.897, 0.892 and 0.889, respectively; p>0.05), standard non-AI automatic MC (AUC=0.877; p>0.05) and significantly higher than No-MC (AUC=0.835; p<0.05). Similar findings were observed with MFR. The 95% confidence limits for agreement with the operator were ±0.49ml/g/min (mean difference = 0.00) for MFR and ±0.24ml/g/min (mean difference = 0.00) for MBF. Conclusion: DL-MC is significantly faster but diagnostically comparable to manual-MC. The quantitative results obtained with DL-MC for MBF and MFR are in excellent agreement with those manually corrected by experienced operators compared to standard non-AI automatic MC in patients undergoing

Indexed as

18F-flurpiridazdeep learningmotion correctionmyocardial blood flowmyocardial flow reservePET

Identifiers

PMID40630596
PMCPMC12236872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.